A multiphase product for contraception comprising: a first phase of 2 daily dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily dosage units, a first group comprising 5 daily dosage units, each of which comprises 2 mg of estradiol valerate and 2 mg of dienogest, and a second group comprising 17 daily dosage units, each of which comprises 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 two daily dosage units, each comprising 1 mg of estradiol valerate, and a fourth phase of 2 two daily dosage units, each comprising a pharmaceutically acceptable placebo. view more

A multiphase oral contraception product comprising: a first phase of 2 daily oral dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily oral dosage units, a first group comprising 5 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 2 mg of dienogest, and a second group comprising 17 daily oral dosage units, each of which comprises 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily oral dosage units, each comprising 1 mg of estradiol valerate, and a fourth phase of 2 daily oral dosage units, each comprising a pharmaceutically acceptable placebo. view more

A method of oral contraception comprising orally administering to a woman: one oral dosage unit comprising 3 mg of estradiol valerate daily for 2 days, then one oral dosage unit comprising 2 mg of estradiol valerate and 2 mg of dienogest daily for 5 days, then one oral dosage unit comprising 2 mg of estradiol valerate and 3 mg of dienogest daily for 17 days, then one oral dosage unit comprising 1 mg of estradiol valerate daily for 2 days, and then one oral dosage unit comprising a pharmaceutically acceptable placebo daily for 2 days. view more